Wellfully Overview

  • Founded
  • 1992

  • Status
  • Public

  • Employees
  • 1

  • Stock Symbol
  • WFL

Stock Symbol
  • Investments
  • 1

  • Share Price
  • $0.03

  • (As of Thursday Closing)

Wellfully General Information


Wellfully Ltd is engaged in the research and development for Dermaportation and ETP transdermal drug delivery technologies. The company operates in segments namely development of the dermaportation drug delivery technology and Devices segments. Geographically, it derives a majority of revenue from Singapore and also has a presence in Japan. It serves Pharmaceutical; Cosmetics and Skincare and Consumer Healthcare industries.

Contact Information

Formerly Known As
Ownership Status
Publicly Held
Financing Status
Primary Industry
Drug Delivery
Stock Exchange
Primary Office
  • 284 Oxford Street
  • Leederville, Western Australia 6007
  • Australia

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Wellfully Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.03 $0.03 $0.02 - $0.14 $7.65M 275M 736K

Wellfully Financials Summary

In Thousands,
TTM 30-Jun-2022 FY 2022 30-Jun-2022 FY 2021 30-Jun-2021 FY 2020 30-Jun-2020
EV 7,744 7,744 6,032
Revenue 297 45
EBITDA (4,688) (2,498)
Net Income (4,769) (2,487)
Total Assets 2,549 819
Total Debt 198 718
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Wellfully Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Wellfully‘s full profile, request access.

Request a free trial

Wellfully Patents

Wellfully Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2011519638-A Method and apparatus for promoting transdermal diffusion Pending 07-May-2008 000000000 0
EP-2303393-A4 Method and apparatus for enhanced transdermal diffusion Withdrawn 07-May-2008 000000000 0
EP-2303393-A1 Method and apparatus for enhanced transdermal diffusion Withdrawn 07-May-2008 000000000 0
US-20110201869-A1 Method and apparatus for enhanced transdermal diffusion Abandoned 07-May-2008 000000000 00
AU-2008355879-A1 Method and apparatus for enhanced transdermal diffusion Abandoned 07-May-2008 A61M37/00
To view Wellfully’s complete patent history, request access »

Wellfully Executive Team (2)

Name Title Board Seat Contact Info
Paul Peros Chief Executive Officer
Jeffrey Edwards Founder & Director
To view Wellfully’s complete executive team members history, request access »

Wellfully Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Wellfully Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 000 18-Feb-2020 0000000000 0000 Food Products
To view Wellfully’s complete acquisitions history, request access »

Wellfully Subsidiaries (1)

Company Name Industry Location Founded
000000000 0000000 Food Products Arndell Park, Australia
To view Wellfully’s complete subsidiaries history, request access »